✦ LIBER ✦

Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer

✍ Scribed by Apple, Sophia K; Lowe, Alarice C; Rao, P Nagesh; Shintaku, I Peter; Moatamed, Neda A

Book ID: 109887837
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 191 KB
Volume: 22
Category: Article
ISSN: 0893-3952
DOI: 10.1038/modpathol.2009.82

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of her2-neu status in core ne

Assessment of her2-neu status in core needle biopsy of 215 patients with primary breast cancer

✍ S. Taucher; M. Rudas; M. Gnant; D. Kandioler; P. Dubsky; Th. Bachleitner; S. Rok 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 197 KB

Comparison of Immunohistochemical and Fl

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment for HER-2/neu Status in Taiwanese Breast Cancer Patients

✍ Shou-Jen Kuo; Boris Bao-Tyan Wang; Cheng-Shyong Chang; Tze-Ho Chen; Kun-Tu Yeh; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Chromogenic in situ hybridization for He

Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization

✍ Doris Mayr; Sibylle Heim; Kerstin Weyrauch; Evelyn Zeindl-Eberhart; Anne Kunz; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

0021 The discrepancy between results of

0021 The discrepancy between results of HER2 receptors in needle biopsy and surgical specimen of breast cancer

✍ N. Sikorsky; L. Leitzin; Z. Shklar; R. Rubinov; M. Shtainer 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Comparison of HER-2 status determined by

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

✍ Yun Gong; Daniel J. Booser; Nour Sneige 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND Accurate assessment of __HER‐2__ status is necessary prior to anti‐__HER‐2__ antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess __HER‐2__ status in the primary tumor or in metastatic lesions. It is also

0025 A comparative study of immunohistoc

0025 A comparative study of immunohistochemical staining and fluorescence in situ hybridization method of HER-2/neu in breast cancer

✍ M. Koo; B. Moon; K. Choi; C. Yom; Y. Park 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB